Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12964404 | 0.94 | SIGMAR1 (0.48) | SIGMAR1AVPR1A | |
| SCHEMBL12964401 | 0.94 | SIGMAR1 (0.48) | SIGMAR1AVPR1A | |
| SCHEMBL14112077 | 0.91 | SIGMAR1 (0.47) | SIGMAR1AVPR1AOPRD1 | |
| SCHEMBL8553572 | 0.91 | SIGMAR1 (0.52) | SIGMAR1AVPR1AOPRD1 | |
| SCHEMBL12964451 | 0.85 | SIGMAR1 (0.59) | SIGMAR1 | |
| SCHEMBL8557116 | 0.84 | SIGMAR1 (0.52) | SIGMAR1AVPR1A | |
| SCHEMBL6919513 | 0.83 | SIGMAR1 (0.57) | SIGMAR1OPRD1 | |
| SCHEMBL19121681 | 0.81 | SIGMAR1 (0.59) | SIGMAR1 | |
| SCHEMBL12964402 | 0.81 | OPRL1 (0.45) | SIGMAR1AVPR1A | |
| SCHEMBL30508284 | 0.80 | SLC6A4 (0.36) | SIGMAR1AVPR1AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-10669258-B2 | 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190308948-A1 | 3-SULFONYL-5-AMINOPYRIDINE-2,4-DIOL APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| US-10392347-B2 | 2,4-dihydroxy-nicotinamides as APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-16 | — | — | US | disclosed |
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-20150152113-A1 | Positive Allosteric Modulators of MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-04 | — | — | US | disclosed |
| US-20150031678-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE S.A. (ES) | 2015-01-29 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8664216-B2 | Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2356123-B1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2010054961-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | AP2A1, P2RX5, AP3M1 | SIGMAR1 218/4885AVPR1A 705/4885OPRD1 73/4885 |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | SIGMAR1 244/4885AVPR1A 471/4885OPRD1 173/4885 |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | AVPR1A, OXTR, AVPR1B | SIGMAR1 123/4885AVPR1A 1/4885OPRD1 13/4885 |
| US-20150152113-A1 | Positive Allosteric Modulators of MGLUR2 | GRM2, GRM1, GRIN2A | SIGMAR1 161/4885AVPR1A 757/4885OPRD1 68/4885 |
| US-10392347-B2 | 2,4-dihydroxy-nicotinamides as APJ agonists | NADK, VDR, P2RY2 | SIGMAR1 3009/4885AVPR1A 821/4885OPRD1 1013/4885 |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885AVPR1A 842/4885OPRD1 581/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885AVPR1A 842/4885OPRD1 581/4885 |
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | SIGMAR1 1623/4885AVPR1A 364/4885OPRD1 808/4885 |
| US-20150031678-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES, THEIR PREPARATION AND USE AS MEDICAMENTS | SIGMAR1, P2RX5, P2RY1 | SIGMAR1 1/4885AVPR1A 447/4885OPRD1 21/4885 |
| US-10669258-B2 | 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonists | AP3D1, KCNJ5, TBXA2R | SIGMAR1 478/4885AVPR1A 486/4885OPRD1 135/4885 |
| US-20190308948-A1 | 3-SULFONYL-5-AMINOPYRIDINE-2,4-DIOL APJ AGONISTS | AP3D1, KCNJ5, TBXA2R | SIGMAR1 478/4885AVPR1A 486/4885OPRD1 135/4885 |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885AVPR1A 842/4885OPRD1 581/4885 |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885AVPR1A 842/4885OPRD1 581/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885AVPR1A 842/4885OPRD1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.